Trial Profile
A Phase I/II Study of Preoperative (Neoadjuvant) Combination of Letrozole (Femara), Everolimus (Afinitor), and TRC105 in Postmenopausal Women With Newly Diagnosed Local or Locally Advanced Potentially Resectable Hormone-Receptor Positive and Her2 Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Carotuximab (Primary) ; Everolimus; Letrozole
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
- Focus Adverse reactions
- 15 Aug 2023 Status changed from active, no longer recruiting to completed.
- 01 Apr 2023 Results published in the Breast Cancer Research and Treatment
- 13 Dec 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.